DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,054 filers reported holding DANAHER CORPORATION in Q4 2021. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,277,229 | -66.1% | 49,485 | -67.2% | 1.07% | -39.9% |
| Q2 2023 | $36,234,720 | +1.5% | 150,978 | +6.5% | 1.78% | +4.7% |
| Q1 2023 | $35,716,336 | +5.5% | 141,709 | +11.1% | 1.70% | +6.4% |
| Q4 2022 | $33,851,667 | +156.5% | 127,540 | +149.6% | 1.60% | +104.7% |
| Q3 2022 | $13,198,000 | -16.8% | 51,097 | -18.4% | 0.78% | +5.4% |
| Q2 2022 | $15,871,000 | -18.4% | 62,602 | -5.6% | 0.74% | -5.2% |
| Q1 2022 | $19,453,000 | -1.1% | 66,319 | +11.0% | 0.78% | +11.8% |
| Q4 2021 | $19,665,000 | -19.6% | 59,770 | -25.6% | 0.70% | -9.0% |
| Q3 2021 | $24,469,000 | -28.6% | 80,374 | -37.0% | 0.77% | -4.8% |
| Q2 2021 | $34,261,000 | +51.1% | 127,668 | +26.7% | 0.81% | +47.9% |
| Q1 2021 | $22,675,000 | -19.4% | 100,744 | -20.4% | 0.55% | -8.5% |
| Q4 2020 | $28,116,000 | -16.7% | 126,569 | -19.3% | 0.60% | -19.5% |
| Q3 2020 | $33,762,000 | +2.6% | 156,792 | -15.8% | 0.74% | +2.9% |
| Q2 2020 | $32,917,000 | +34.5% | 186,148 | +5.3% | 0.72% | +23.8% |
| Q1 2020 | $24,471,000 | +32.1% | 176,800 | +46.4% | 0.58% | +40.5% |
| Q4 2019 | $18,531,000 | -1.4% | 120,740 | -7.2% | 0.42% | -3.7% |
| Q3 2019 | $18,791,000 | -7.8% | 130,105 | -8.8% | 0.43% | -7.3% |
| Q2 2019 | $20,379,000 | -2.7% | 142,589 | -10.1% | 0.46% | -2.7% |
| Q1 2019 | $20,944,000 | +24.0% | 158,643 | -3.1% | 0.48% | +15.5% |
| Q4 2018 | $16,884,000 | -2.9% | 163,728 | +2.4% | 0.41% | +8.1% |
| Q3 2018 | $17,380,000 | +4.3% | 159,946 | -5.3% | 0.38% | -2.8% |
| Q2 2018 | $16,662,000 | -0.0% | 168,850 | -0.8% | 0.39% | -2.2% |
| Q1 2018 | $16,663,000 | +91.0% | 170,184 | +81.1% | 0.40% | +101.5% |
| Q4 2017 | $8,723,000 | +167.3% | 93,975 | +147.0% | 0.20% | +170.3% |
| Q3 2017 | $3,263,000 | +1.7% | 38,041 | 0.0% | 0.07% | +2.8% |
| Q2 2017 | $3,210,000 | +25.4% | 38,041 | +27.1% | 0.07% | +26.3% |
| Q1 2017 | $2,559,000 | +73.3% | 29,923 | +57.7% | 0.06% | +72.7% |
| Q4 2016 | $1,477,000 | -47.6% | 18,980 | -37.4% | 0.03% | -51.5% |
| Q4 2015 | $2,817,000 | -57.8% | 30,334 | -61.2% | 0.07% | -59.5% |
| Q3 2015 | $6,668,000 | +121.3% | 78,256 | +120.5% | 0.17% | +184.7% |
| Q1 2015 | $3,013,000 | +697.1% | 35,490 | +639.4% | 0.06% | +883.3% |
| Q2 2014 | $378,000 | – | 4,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |